





United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/328,742		06/06/1999	ALEXANDROS MAKRIYANNIS	UCON/141/US	7228
2543	7590	10/31/2003		EXAMINER	
ALIX YAL		TAS LLP	PRYOR, ALTON NATHANIEL		
750 MAIN STREET SUITE 1400				ART UNIT	PAPER NUMBER
HARTFORI	O, CT 06	5103		1616	*
				DATE MAILED: 10/31/2003	7/

Please find below and/or attached an Office communication concerning this application or proceeding.

. 10		Application No.	Applicant(s)					
		09/328,742	MAKRIYANNIS ET AL.					
	Office Action Summary	Examiner	Art Unit					
		Alton N. Pryor	1616					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status 1)□	Responsive to communication(s) filed on <u>20 A</u>	Jugust 2003						
2a)□	•							
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims								
4) Claim(s) 1-22 is/are pending in the application.								
4a) Of the above claim(s) 4,7-11,15,18-20 and 22 is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.								
6)								
7)	7) Claim(s) is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.								
Application	on Papers							
9)☐ The specification is objected to by the Examiner.								
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
	1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No							
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)					



Art Unit: 1616

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-3,5,12-14,16,17,21 are rejected under 35 U.S.C. 102(b) as being anticipated by Khanolkar et al (J. Of Medicinal Chemistry (1996), 39 (22), 4515-9. Khanolkar teaches a method of administering an instant compound of formula X-Y-Z to an animal. Khanolkar teaches the instant compound where X = AA (arachidonic acid moiety), Y = amide group, and Z = 3-hydroxy piperidine ring. See abstract. Note that instant composition claims read as compound claims.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-3,5,12-14,16,17,21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Khanolkar as applied to claims 1-3,5,12-14,16,17,21. See 35 USC 102(b). Khanolkar teaches all that is recited in the elected species except for the invention where Z = 4-hydroxypiperidine ring. It would have been obvious to one having ordinary skill in the art to make the instant invention with the 4-hydroxypiperidine

Application/Control Number: 09/328,742

Art Unit: 1616

Page 3

subsistent. One would have been motivated to do this since the 3-hydroxypiperidine and 4-hydroxypiperidine are positional isomers only differing in the positioning of the hydroxy group on the piperidine ring. In the absence of unexpected results, one would except for the isomers to offer similar activity.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 703 308-4691. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 703-308-2927. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-1235.

Primary Examiner

PRIMARY EXAMINER

AU 1616